Literature DB >> 23708607

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Marie Pancera1, Syed Shahzad-Ul-Hussan, Nicole A Doria-Rose, Jason S McLellan, Robert T Bailer, Kaifan Dai, Sandra Loesgen, Mark K Louder, Ryan P Staupe, Yongping Yang, Baoshan Zhang, Robert Parks, Joshua Eudailey, Krissey E Lloyd, Julie Blinn, S Munir Alam, Barton F Haynes, Mohammed N Amin, Lai-Xi Wang, Dennis R Burton, Wayne C Koff, Gary J Nabel, John R Mascola, Carole A Bewley, Peter D Kwong.   

Abstract

HIV-1 uses a diverse N-linked-glycan shield to evade recognition by antibody. Select human antibodies, such as the clonally related PG9 and PG16, recognize glycopeptide epitopes in the HIV-1 V1-V2 region and penetrate this shield, but their ability to accommodate diverse glycans is unclear. Here we report the structure of antibody PG16 bound to a scaffolded V1-V2, showing an epitope comprising both high mannose-type and complex-type N-linked glycans. We combined structure, NMR and mutagenesis analyses to characterize glycan recognition by PG9 and PG16. Three PG16-specific residues, arginine, serine and histidine (RSH), were critical for binding sialic acid on complex-type glycans, and introduction of these residues into PG9 produced a chimeric antibody with enhanced HIV-1 neutralization. Although HIV-1-glycan diversity facilitates evasion, antibody somatic diversity can overcome this and can provide clues to guide the design of modified antibodies with enhanced neutralization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708607      PMCID: PMC4046252          DOI: 10.1038/nsmb.2600

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  60 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4.

Authors:  Christian St-Pierre; Hiroshi Manya; Michel Ouellet; Gary F Clark; Tamao Endo; Michel J Tremblay; Sachiko Sato
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

3.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 6.  Expression systems for therapeutic glycoprotein production.

Authors:  Yves Durocher; Michael Butler
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

7.  Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.

Authors:  Lai-Xi Wang; Jiahong Ni; Suddham Singh; Hengguang Li
Journal:  Chem Biol       Date:  2004-01

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Vaccinology: A sweet cleft in HIV's armour.

Authors:  Quentin J Sattentau
Journal:  Nature       Date:  2011-12-14       Impact factor: 49.962

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  182 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 3.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

4.  Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.

Authors:  Laura K Pritchard; Daniel I R Spencer; Louise Royle; Snezana Vasiljevic; Stefanie A Krumm; Katie J Doores; Max Crispin
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 5.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 6.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

7.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

8.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Authors:  Louise Scharf; Johannes F Scheid; Jeong Hyun Lee; Anthony P West; Courtney Chen; Han Gao; Priyanthi N P Gnanapragasam; René Mares; Michael S Seaman; Andrew B Ward; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

9.  Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.

Authors:  Sabrina Lusvarghi; Katheryn Lohith; Jeanne Morin-Leisk; Rodolfo Ghirlando; Jenny E Hinshaw; Carole A Bewley
Journal:  ACS Infect Dis       Date:  2016-10-03       Impact factor: 5.084

Review 10.  Synthetic carbohydrate antigens for HIV vaccine design.

Authors:  Lai-Xi Wang
Journal:  Curr Opin Chem Biol       Date:  2013-12       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.